AstraZeneca reports positive results for Imfinzi MIBC regimen
AstraZeneca (AZN) has reported positive results from an analysis of its NIAGARA Phase 3 study of Imfinzi in the treatment of ...
pulmonologyadvisor13h
Eosinophilic Asthma: Benralizumab Effective in Severe Disease
Severe eosinophilic is effectively treated with benralizumab, with especially good outcomes in patients with high BEC and high FeNO.
Is AstraZeneca PLC (AZN) the Best Foreign Dividend Stock to Buy According to Analysts?
We recently compiled a list of the 13 Best Foreign Dividend Stocks To Buy According to Analysts. In this article, we are ...
The Lancet1d
Patient in her 70s with COPD and asthma improving significantly since using monoclonal antibody dupilumab
Lyn Iemma, aged 75 years at the time of writing, would not describe her life as dramatic. Born and raised in Perth, WA, Australia, this thriving but relaxed city is the place she has always called ...
hospitalhealthcare1d
Chronic asthma guideline key updates and implications: diagnosis and management
Ravijyot Saggu explores key updates and implications of the new joint chronic asthma guidelines for diagnosis and monitoring.
BioSpace2d
SpringWorks Wins FDA Nod for Neurofibromatosis Drug, Tees Up Challenge to AstraZeneca
The FDA on Tuesday signed off on SpringWorks Therapeutics’ mirdametinib—now to carry the brand name Gomekli—for the treatment ...
The Lancet4d
Management and mechanisms of eosinophil action in asthma: mind the gap?
The SARS-CoV-2 pandemic interrupted much respiratory research. Respiratory clinical academics joined colleagues in providing clinical care, and global research efforts were directed to finding new ...
Could Your Fatigue and Breathing Symptoms Be EGPA?
An estimated 5,000 people in the United States are living with Eosinophilic Granulomatosis with Polyangiitis (EGPA), a rare ...